Modeling therapeutic strategies in rheumatoid arthritis: Use of decision analysis and Markov models

Citation
Da. Albert et al., Modeling therapeutic strategies in rheumatoid arthritis: Use of decision analysis and Markov models, J RHEUMATOL, 27(3), 2000, pp. 644-652
Citations number
38
Categorie Soggetti
Rheumatology,"da verificare
Journal title
JOURNAL OF RHEUMATOLOGY
ISSN journal
0315162X → ACNP
Volume
27
Issue
3
Year of publication
2000
Pages
644 - 652
Database
ISI
SICI code
0315-162X(200003)27:3<644:MTSIRA>2.0.ZU;2-S
Abstract
Objective. The management of patients with rheumatoid arthritis (RA) is con troversial, with a number of different proposed treatment strategies based on different conceptions of the natural history of the disease and differen t interpretations of the efficacy and effectiveness of the drugs used for t reatment. We attempted to develop a theoretical framework to assess the eff ectiveness of different treatment regimens for RA. Methods, We used decision analysis to structure the problem of comparing se quential monotherapy to a combination strategy. Subsequently, we used 3 dif ferent estimates of drug effectiveness: one from expert rheumatologists; a metaanalysis; and a recent nationwide survey of American rheumatologists, i n a Markov model. Last, we utilized published duration of therapy data to m odel drug treatment over time. Results. Estimates of drug effectiveness differed substantially among rheum atologists, but regardless of the estimates and the treatment strategy used , the model predicted over 90% of patients improved by the 3rd drug trial. Over time, treatment patterns in our model resemble the "sawtooth" pattern previously observed. Conclusion, Treatment strategies in RA are difficult to model because of un certainty in both the structure of the model and the data needed to perform the analysis. These models tend to overestimate the effectiveness of drug sequences because of nonindependence between therapies, probably due to seq uence effects, a change in responsiveness over time, or resistant subgroups . Our preliminary analysis suggests that the most effective agent, possibly methotrexate. should be used first if the objective is to get as many pati ents into remission as quickly as possible.